NCT04119154View on ClinicalTrials.gov

Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)

NACompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

September 20, 2021

Study Completion Date

September 20, 2021

Conditions
Breast NeoplasmsLymphoma
Interventions
DIAGNOSTIC_TEST

Contrast Microhalography (CEM)

Fine needle aspirates evaluated by CEM device

Trial Locations (1)

Unknown

Botswana Harvard AIDS Institute, Gaborone

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Botswana Harvard AIDS Institute Partnership

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Harvard School of Public Health (HSPH)

OTHER

NCT04119154 - Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza) | Biotech Hunter | Biotech Hunter